Masitinib found to be an effective COVID-19 treatment in mouse model
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
List view / Grid view
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
Researchers have revealed that the immune system of obese mice treated with TSLP released lipids through sebaceous glands.
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
Researchers have added to evidence that farnesol prevents and reverses brain damage linked to Parkinson’s disease in mouse models.
Scientists have shown that manipulating the perineuronal nets (PNNs) in the brains of mice led to the reversal of age-related memory loss.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
A non-invasive, label-free optical method can produce high-resolution imaging of cellular brain diseases in vivo.
A US team has designed a high-quality, high-speed imaging system that could lead to new understandings of complex tissue specimens.
A team have developed a minimally invasive exosome spray that helped repair rat hearts after myocardial infarction.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.